At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
APR-246 (eprenetapopt) + Pembrolizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
In Brief
A Phase 2 clinical trial evaluating APR-246 (eprenetapopt) + Pembrolizumab for Bladder Cancer and 5 related conditions. Completed, enrolled 40 participants across 8 sites.
Detailed Summary
A phase 1/2, open-label, study to determine the safety and preliminary efficacy of APR-246 in combination with pembrolizumab in subjects with solid tumor malignancies. The study will include a safety lead-in portion followed by a phase 2 expansion portion in specific disease groups.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Cancer, Gastric Cancer, Non Small Cell Lung Cancer, NSCLC, Urothelial Carcinoma, Advanced Solid Tumor
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartJun 2020
Primary CompletionApr 2022
TodayJul 2026
First PostedMay 12, 2020
Enrollment StartJun 25, 2020
Primary CompletionApr 30, 2022
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 6.1 years ago
Interventions
APR-246 (eprenetapopt) + Pembrolizumabdrug
APR-246 D1-4 + Pembrolizumab D3